Suchergebnisse - "Peterlin, Pierre"

PubPharm (153)

41

Interest of a third dose of BNT162b2 anti-SARS-CoV-2 messenger RNA vaccine after allotransplant

enthalten in: British journal of haematology | 2022

von Le Bourgeois, A. | Coste-Burel, M. | Guillaume, T. | +17

42

SARS-CoV-2 T-Cell Responses in Allogeneic Hematopoietic Stem Cell Recipients following Two Doses of BNT162b2 mRNA Vaccine

enthalten in: Vaccines | 2022

von Clémenceau, B. | Guillaume, T. | Coste-Burel, M. | +9

43

Dramatic Recovery after Etoposide Phosphate Infusion for Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome following Treatment with Tisagenlecleucel in a Young Patient with Relapsed Acute Lymphoblastic Leukemia : A Case Report

enthalten in: Acta haematologica | 2022

von Peterlin, P. | Garnier, A. | Le Bourgeois, A. | +6

44

Safety and antibody response after one and/or two doses of BNT162b2 Anti-SARS-CoV-2 mRNA vaccine in patients treated by CAR T cells therapy

enthalten in: British journal of haematology | 2022

von Gastinne, T. | Le Bourgeois, A. | Coste-Burel, M. | +17

45

Safety and antibody response after one and/or two doses of BNT162b2 Anti‐SARS‐CoV‐2 mRNA vaccine in patients treated by CAR T cells therapy

enthalten in: British Journal of Haematology | 2022

von Gastinne, T. | Le Bourgeois, A. | Coste‐Burel, M. | +17

46

Interest of a third dose of BNT162b2 anti‐SARS‐CoV‐2 messenger RNA vaccine after allotransplant

enthalten in: British Journal of Haematology | 2022

von Le Bourgeois, A. | Coste‐Burel, M. | Guillaume, T. | +17

47

A randomised phase II study of azacitidine ( AZA) alone or with Lenalidomide ( LEN), Valproic acid ( VPA) or Idarubicin ( IDA) in higher‐Risk MDS or low blast AML : GFM's “pick a winner” trial, with the impact of somatic mutations

enthalten in: British Journal of Haematology | 2022

von Adès, L. | Duployez, N. | Guerci‐Bresler, A. | +27

48

Effectiveness of a third dose of BNT162b2 anti‐SARS‐CoV‐2 mRNA vaccine over a 6‐month follow‐up period in allogenic hematopoietic stem cells recipients

enthalten in: Hematological Oncology | 2022

von Chevallier, P. | Jullien, M. | Peterlin, P. | +5

49

Peripheral levels of monocytic myeloid‐derived suppressive cells before and after first induction predict relapse and survivals in AML patients

enthalten in: Journal of Cellular and Molecular Medicine | 2022

von Peterlin, P. | Debord, C. | Eveillard, M. | +6

50

Anti‐SARS‐CoV‐2 vaccines in recipient and/or donor before allotransplant

enthalten in: eJHaem | 2022

von Jullien, M. | Coste‐Burel, M. | Clemenceau, B. | +13